Clinical Trial: Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Phase 4 Study of Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD

Brief Summary: The safety and efficacy of Caltriol on mild proteinuria (<1.0g/d) reduction in CKD patients.

Detailed Summary: Proteinuria is not only a capital sign of kidney disease, but also a marker of chronic kidney disease (CKD) progression. Emerging evidence in patients with CKD show that vitamin D and its analogs can reduce proteinuria or albuminuria in the presence of angiotensin-converting enzyme inhibithion. While some of the studies reported that vitamin D receptor activation has been associated with increased serum creatinine and reduced estimated glomerular filtration rates. Therefore, the investigators plan to conduct a randomized clinical study to evaluate the efficacy and safety of Calcitriol in the treatment of mild proteinuria (<1.0g/d) CKD patients,which has no specific treatment at present.
Sponsor: Huashan Hospital

Current Primary Outcome: the percentage change of proteinuia [ Time Frame: 24 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome: the proportion of patients achieving at least a 15% decrease in proteinuria [ Time Frame: 24 weeks ]

Original Secondary Outcome: Same as current

Information By: Huashan Hospital

Dates:
Date Received: March 19, 2013
Date Started: March 2013
Date Completion: June 2015
Last Updated: March 28, 2013
Last Verified: March 2013